Is there any role for administering another course of recombinant zoster vaccine (Shingrix) in a previously vaccinated patient with RA, who is in clinical remission on JAK inhibitor but has had a breakthrough shingles infection?
The last SHINGRIX was about 4 years ago and both doses were given.
Community PollStarted
Would you administer another course of the recombinant zoster vaccine for a patient with rheumatoid arthritis in clinical remission on a JAK inhibitor who has experienced a breakthrough shingles infection?
92 physicians have voted
Join Mednetto vote and see how they answered.
2 Answers
Mednet Member
Infectious Disease · Saint Francis Hospital
Answered on
Dr. @Dr. First Last has provided a very complete and literate response. However, the critical word is “likely”. As with most vaccines, both the strength and the duration of response to the zoster vaccine decline with worsening levels of immunosuppression.
We have increasingly adopted the practice of...
Join for free or sign in to see the full answer
Mednet Member
Infectious Disease · Washington University in St. Louis
Answered on
Recombinant zoster vaccine is quite immunogenic compared to other vaccines, so an immunocompromised person who previously received the 2-dose course (especially before severe immunosuppression with a Jak inhibitor) is likely to have a robust immune response and protection against zoster for many yea...
Join for free or sign in to see the full answer